Riskpilot← Back to searchSign inGet full accessNORDIC BIOSCIENCE CLINICAL DEVELOPMENT VII A/S
A/SIn liquidationCVR 33249098Herlev Hovedgade 82Forskning og eksperimentel udvikling indenfor bioteknologi · NACE 721100Est. 2010— employees
Revenue 2019
DKK 248K
-81% vs 2018
EBITDA margin
88.7%
-83% vs 2018
Equity ratio
68.2%
Financial strength
Net profit 2019
DKK 165K
-83% vs 2018
| Revenue | DKK 248K | -81% |
| EBITDA | DKK 220K | -83% |
| Net profit | DKK 165K | -83% |
| Total assets | DKK 1,1M | -88% |
| Equity | DKK 725K | -50% |
| Employees | — | — |
Legal name
NORDIC BIOSCIENCE CLINICAL DEVELOPMENT VII A/S
CVR number
33249098
Legal form
Aktieselskab
NACE code
721100 · Forskning og eksperimentel udvikling indenfor bioteknologi
Founded
18. oktober 2010
Share capital
DKK 500.000
Employees
—
VAT registered
No
Audit selected
No
Last report
2019-12-31
Financial year
January – December
Signatory rights
Virksomheden tegnes af en likvidator
Address
Herlev Hovedgade 82
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | -2.238 | 4.173 | 41.982 | 60.442 | 15.991 | 2.861 | 1.318 | 248 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -1.117 | 4.130 | 41.762 | 60.562 | 15.958 | 2.831 | 1.289 | 220 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -1.117 | 4.130 | 41.762 | 60.562 | 15.958 | 2.831 | 1.289 | 220 |
| Net financials | -66 | 97 | 1.139 | -1.285 | -1.653 | -282 | -71 | -9 |
| Profit before tax | -1.184 | 4.228 | 42.902 | 59.277 | 14.305 | 2.549 | 1.219 | 211 |
| Tax | 592 | 1.057 | 10.551 | 13.890 | 3.252 | 578 | 264 | 46 |
| Net profit | -1.775 | 3.171 | 32.351 | 45.386 | 11.053 | 1.972 | 954 | 165 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Total assets | 71.563 | 96.730 | 65.983 | 49.834 | 70.142 | 7.610 | 8.782 | 1.063 |
| Equity | 3.073 | 6.244 | 38.595 | 45.982 | 12.034 | 3.006 | 1.460 | 725 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 68.489 | 90.486 | 27.388 | 3.852 | 58.108 | 4.604 | 7.322 | 338 |
| Total debt | 68.489 | 90.486 | 27.388 | 3.852 | 58.108 | 4.604 | 7.322 | 338 |
EBITDA margin
88.7%
This company
15.8%
Market median
+461% vs market
20122019
Equity ratio
68.2%
This company
38.2%
Market median
+79% vs market
20122019
Return on equity
22.7%
This company
18.4%
Market median
+23% vs market
20122019
Net profit margin
66.4%
This company
8.1%
Market median
+720% vs market
20122019
Asset turnover
0.23×
This company
1.12×
Market median
-79% vs market
20122019
Debt / equity
0.47×
This company
0.62×
Market median
+24% vs market
20122019
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-01-01 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
BJ Management | Management | 2010 | — | — |
JR Chief Executive Officer | Chief Executive Officer | 2014 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2010 | — | — | |
| Chairman | 2010 | — | — | |
| Board of Directors | 2010 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
NBCD A/S | Company | 100.0% | 100.0% | 2010 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of NORDIC BIOSCIENCE CLINICAL DEVELOPMENT VII A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Bente Juel Christiansen | Management | 0 companies |
| Jeppe Ragnar Andersen | Chief Executive Officer | 0 companies |
| Thomas Nielsen | Board of Directors | 0 companies |
| Claus Henrik Christiansen | Chairman | 0 companies |
| Morten Asser Karsdal | Board of Directors | 0 companies |